Search Bar & Filters
Found 5 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating treatments for amblyopia in children aged 4 to 7 years. The study compares watching dichoptic movies or shows using the Luminopia virtual reality headset for 1 hour a day, 6 days a week, against patching the fellow eye for 2 hours a day, 7 days a week. The goal is to see if the dichoptic treatment is not worse than patching in improving distance visual acuity in the amblyopic eye over 26 weeks. Participants are randomly assigned to one of two groups the Luminopia group, who watch dichoptic content through a headset daily, or the patching group, who wear an eye patch for specified times. After 26 weeks, if participants in the patching group do not show sufficient improvement, they are offered the Luminopia therapy with follow-up visits at weeks 39 and 52. Those who do not qualify for this extension end the study after 26 weeks. During the study, participants undergo clinical assessments at 13 and 26 weeks post-randomization to measure changes in vision. Follow-up visits are scheduled for participants who switch to Luminopia after patching if needed. Researchers monitor adherence to treatment, visual acuity changes, and any safety concerns throughout the trial, which lasts up to 52 weeks for some participants.
Actively Recruiting
This research is evaluating dichoptic treatments for children aged 8 to 12 years with amblyopia, a vision condition. Participants will be randomly assigned to one of three groups wearing the Luminopia headset to watch dichoptic movies, using the Vivid Vision headset to play dichoptic games, or continuing with optical correction alone if needed. The study aims to compare these approaches to improve visual acuity in the amblyopic eye. Participants assigned to the Luminopia group will watch dichoptic movies or shows for one hour daily, six days per week, while using their prescribed optical correction if needed. The Vivid Vision group will play dichoptic games using a virtual reality headset for approximately 25 minutes daily, six days per week, also with optical correction if required. The third group will continue full-time optical correction alone. At 18 weeks, those initially on optical correction alone who show significant vision difference may be offered a chance to try either dichoptic treatment, with follow-up visits extending to 36 weeks. Throughout the study, participants will have clinical assessments at 9 and 18 weeks after starting treatment. Those switching to dichoptic therapy after 18 weeks will have additional visits at 27 and 36 weeks. Researchers will measure changes in visual acuity of the amblyopic eye and assess quality of life through questionnaires. The study includes monitoring adherence to treatments and continues for up to 36 weeks for some participants, with safety and effectiveness evaluated during follow-up visits.
Actively Recruiting
Researchers are evaluating if one day of post-operative prone head positioning is as effective as seven days in patients with retinal detachments involving inferior retinal breaks after pars plana vitrectomy PPV using perfluoropropane C3F8 gas as a tamponade. This single-arm phase II study uses a Simons two-stage design to assess anatomical retina success rates and determine if shorter head positioning is promising for further research. Participants will receive retina re-attachment repair with C3F8 gas tamponade followed by one day of post-operative prone head positioning. The study will enroll 20 patients in two stages 11 patients in the first stage with early stopping rules based on success rates, and if criteria are met, 9 more patients in the second stage. The goal is to achieve retina attachment success in at least 85% of patients. During the study, participants will be monitored for retina attachment using clinical exams with an indirect ophthalmoscope at 3 months and 1 year post-surgery. Researchers will track anatomical success and safety outcomes throughout the follow-up period. The total participation duration varies based on the two-stage design and follow-up assessments. The University of Kansas Medical Center sponsors this trial.
Actively Recruiting
Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.
Actively Recruiting
Researchers are studying the best timing for vitrectomy surgery to remove symptomatic epiretinal membranes ERM, a condition affecting the retina that can cause visual distortion and loss. The trial compares immediate surgery to deferred surgery, which is usually recommended when vision worsens to 2040 or worse. The study aims to understand how delaying surgery impacts visual outcomes, identify factors predicting surgery success or disease progression, and evaluate new measures of visual distortion and reading speed in this condition. Participants are randomly assigned to one of two groups immediate vitrectomy surgery within one month of randomization, or deferred vitrectomy where surgery is performed only if vision declines significantly, symptoms worsen, or complications arise. The deferred group is closely monitored to detect changes that would trigger surgery. This approach helps researchers compare outcomes between early and delayed surgical intervention for ERM. During the study, participants undergo regular vision assessments, including evaluating visual acuity changes over 36 months, which is the primary outcome measure. Researchers also collect data on visual distortion and reading speed to better understand symptoms. Safety and progression are closely monitored, and surgery timing decisions are guided by defined criteria or participant preference. The total study duration extends up to three years, providing long-term insight into ERM management.